Stockscreener 앱 받기
5.04
13.51%
0.60
시간 외 거래:
5.08
0.04
+0.79%
전일 마감가:
$4.44
열려 있는:
$4.47
하루 거래량:
5.08M
Relative Volume:
5.01
시가총액:
$732.77M
수익:
$28.94M
순이익/손실:
$-54.29M
주가수익비율:
-10.85
EPS:
-0.4647
순현금흐름:
$-26.02M
1주 성능:
+4.78%
1개월 성능:
+154.55%
6개월 성능:
+186.36%
1년 성능:
+218.99%
1일 변동 폭
$4.47
$5.43
1주일 범위
$4.32
$5.43
52주 변동 폭
$1.30
$5.43
Omniab Inc Stock (OABI) Company Profile
명칭
Omniab Inc
전화
510-250-7800
주소
5980 HORTON STREET, EMERYVILLE
Compare OABI vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
5.04 | 625.18M | 28.94M | -54.29M | -26.02M | -0.4647 |
VRTX
Vertex Pharmaceuticals Inc
|
556.75 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
852.03 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,055.37 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
150.81 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.23 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2023-11-29 | 개시 | RBC Capital Mkts | Outperform |
| 2023-04-21 | 개시 | The Benchmark Company | Buy |
| 2023-04-13 | 개시 | Craig Hallum | Buy |
| 2023-02-22 | 개시 | Cowen | Outperform |
| 2023-02-13 | 개시 | H.C. Wainwright | Buy |
| 2022-12-20 | 개시 | Truist | Buy |
| 2022-12-16 | 개시 | Credit Suisse | Outperform |
| 2022-11-29 | 개시 | SVB Leerink | Outperform |
| 2022-11-28 | 개시 | Stifel | Buy |
모두보기
Omniab Inc 주식(OABI)의 최신 뉴스
OmniAb (OABI) Quarter in Focus: The Available Earnings Metric Delivers a Beat; Share Move: The Market Price Moves 1.79% Higher at the CloseBanking Earnings Report - vinanet.vn
OmniAb secures up to $370m Lilly deal for ion channel program - BioXconomy
Truist Financial Maintains OmniAb(OABI.US) With Buy Rating - Moomoo
OmniAb signs $370 million ion channel discovery deal with Eli Lilly - The Pharma Letter
OmniAb boosts 2026 cash guidance after milestone-rich Eli Lilly deal validates its biotech platform. - Pluang
M&A Roundup: LEO Pharma Acquires Dersimelagon, BioMarin Acquires Alesta, OmniAb Enters collaboration with Eli Lilly, Chugai and GSK Enter License Agreement for AID351 - Pharmaceutical Executive
Analysts Offer Insights on Healthcare Companies: OmniAb (OABI), Neurocrine (NBIX) and Evaxion Biotech (EVAX) - The Globe and Mail
OmniAb: Lilly-Style Partners Paying Attention To This Early-Stage Biotech (NASDAQ:OABI) - Seeking Alpha
OmniAb Company Profile & Introduction - Moomoo
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $7 - Moomoo
OmniAb Jumps 18% as Lilly Deal Lifts Cash Outlook - TradingView
Eli Lilly Signs $370 Million Ion Channel Deal With OmniAb, Sending Shares Surging - finance.biggo.com
OABI Reiterates by HC Wainwright & Co. -- Price Target Maintained at $11.00 - GuruFocus
Lilly taps OmniAb for ion channel discovery in deal worth up to USD 370m - AllSci
Lilly to pay up to $370M for OmniAb collab; Slate, Fulcrum forge reverse merger - Endpoints News
OmniAb Raises 2026 Financial Guidance - BioSpace
$OmniAb (OABI.US)$ - Moomoo
OmniAb Inc. (OABI) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
OmniAb (OABI) Stock Pops As Earnings Beat Resets Growth Outlook - timothysykes.com
Why Is Omniab Stock Rallying After Eli Lilly Deal? - Benzinga
OmniAb (OABI) Stock Surges After Big Q2 Earnings Beat - StocksToTrade
Why is OmniAb stock surging today? By Investing.com - Investing.com South Africa
OABI Looks 15.8% Overvalued on GF Value™ - GuruFocus
Why is OmniAb stock surging today? - Investing.com
OmniAb (OABI) Jumps As Earnings Beat Fuels Bullish Outlook - StocksToTrade
Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vague - Fierce Biotech
OmniAb raises 2026 cash guidance to $49-$53 million range - scanx.trade
OmniAb lifts 2026 cash outlook following licensing momentum - Yahoo Finance
OmniAb raises 2026 cash guidance on licensing activity By Investing.com - Investing.com Canada
OmniAb Announces Global Collaboration and License Agreement for Ion Channel Program with Eli Lilly & Company - Finviz
OmniAb partners with Eli Lilly on ion channel program By Investing.com - Investing.com Canada
OmniAb raises 2026 cash guidance on licensing activity - Investing.com
OmniAb, Inc. And Eli Lilly And Company Announce Global Collaboration And License Agreement For Ion Channel Program - marketscreener.com
OmniAb lifts 2026 year-end cash outlook to $49 million-$53 million - Bitget
Whitefort Capital group reports 7.1% OmniAb (OABI) ownership in amended filing - Stock Titan
OmniAb (OABI) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Has $2.74 Million Stake in OmniAb, Inc. $OABI - marketbeat.com
OmniAb Inc (OABI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
OABI Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
New Forecasts: Here's What Analysts Think The Future Holds For OmniAb, Inc. (NASDAQ:OABI) - simplywall.st
OmniAb (NASDAQ:OABI) Sets New 1-Year HighTime to Buy? - MarketBeat
Is Now The Time To Look At Buying OmniAb, Inc. (NASDAQ:OABI)? - Moomoo
HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI) - marketbeat.com
Price to sales forward of OmniAb, Inc. – NASDAQ:OABIW - TradingView
OmniAb (NASDAQ:OABI) Jumps After Strong Quarterly Update - Kalkine Media
OmniAb (NASDAQ:OABI) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS - MarketBeat
A Quick Look at Today's Ratings for OmniAb(OABI.US), With a Forecast Between $7 to $11 - Moomoo
OmniAb (OABI) Stock Jumps As Milestones Cut Losses But Risks Linger - Sahm
Craig-Hallum Maintains OmniAb(OABI.US) With Buy Rating, Announces Target Price $7 - 富途牛牛
OmniAb, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:OABI) 2026-08-07 - Seeking Alpha
Stifel Maintains OmniAb(OABI.US) With Buy Rating, Maintains Target Price $9 - news.futunn.com
Omniab Inc (OABI) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Omniab Inc 주식 (OABI) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Option Exercise |
0.00 |
36,459 |
0 |
4,439,736 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '26 |
Sale |
1.49 |
19,244 |
28,674 |
4,420,492 |
3.06%
0.30%
자본화:
|
볼륨(24시간):